# Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context

> **NCT06781450** · — · RECRUITING · sponsor: **IRCCS Azienda Ospedaliero-Universitaria di Bologna** · enrollment: 50 (estimated)

## Conditions studied

- Primary Mediastinal B Cell Lymphoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06781450
- **Lead sponsor:** IRCCS Azienda Ospedaliero-Universitaria di Bologna
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-23
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06781450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06781450, "Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06781450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*